OBM Hepatology and Gastroenterology Editorial Office

2000 Auburn Drive, One Chagrin Highlands

Suite 200, Beachwood, OH 44122


Tel.:  +1-216-370-7293

Fax:  +1-216-378-7505

E-Mail: [email protected]

Current Issue 2018  Archive 2017 

Editor-in-Chief of OBM Hepatology and Gastroenterology

Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.

Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.


The Associate Editor of OBM Hepatology and Gastroenterology

Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.

Special Issue

Exploring Novel Treatment Options for Liver Fibrosis: Can Anti-Angiogenics Succeed?

Submission Deadline: March 31, 2019 (Open)               Submit Now

Guest Editor

Matthias Bartneck
Department of Medicine III, Medical Faculty, RWTH Aachen, Germany
E-Mail: [email protected]
Website: www.bartneck-lab.ukaachen.de
ORC ID: 0000-0003-1516-9610
Research gate: www.researchgate.net/profile/Matthias_Bartneck
Research Interests: Innate immunity; cytokines; macrophages; hepatic stellate cells; cancer cells; liver diseases; cellular immunology; nanomedicine; theranostics

About This Topic

Liver fibrosis is promoted by sustained liver injury which frequently leads to portal hypertension which is accompanied by angiogenic processes. Chronic liver diseases represent a serious global health concern and novel strategies to modulate tissue regeneration are urgently needed. The highly motile immune cells represent a valueable target of exploratory therapies, due to their crosstalk with other cell types such as hepatic stellate cells which generate matrix proteins, and with endothelial cells responsible for blood vessel formation. Three types of drugs compete for therapeutic success in fibrosis treatment: 1) nanomedicines, which have enriched the field of drug delivery, specifically by reducing systemic spreading of drugs; 2) next generation biologicals such as bispecific antibodies which may strongly broaden the options to modulate cellular functionality, while 3) small molecules represent a cost-efficient and safe option.

Planned Papers

Title:Zinc in liver fibrosis
Author: Kurt Grüngreiff
Affiliation: Clinic of Gastroenterology, City Hospital, Magdeburg, 39130 Magdeburg, Birkenallee 34, Germany